04162nam 2200697Ia 450 991097106900332120251017110118.09786610567409978030918090003091809029781280567407128056740697803096609380309660939(CKB)1000000000466038(EBL)3378125(SSID)ssj0000217108(PQKBManifestationID)11209826(PQKBTitleCode)TC0000217108(PQKBWorkID)10202206(PQKB)10182084(Au-PeEL)EBL3378125(CaPaEBR)ebr10141205(CaONFJC)MIL56740(OCoLC)923276964(MiAaPQ)EBC3378125(Perlego)4737056(DNLM)1309055(BIP)13526032(EXLCZ)99100000000046603820060414d2006 uy 0engurcn|||||||||txtccrOvercoming challenges to develop countermeasures against aerosolized bioterrorism agents appropriate use of animal models /Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents, Board on Life Sciences, Institute for Laboratory Animal Research, Division of Earth and Life Studies1st ed.Washington D.C. The National Academies Pressc20061 online resource (88 p.)Description based upon print version of record.9780309102117 0309102111 Includes bibliographical references.""Front Matter""; ""Preface""; ""Contents""; ""Glossary""; ""Summary""; ""1 Introduction""; ""2 Selection or Development of an Animal Model""; ""3 Generation and Characterization of Aerosolized Agents""; ""4 Dosimetry Considerations""; ""5 Experimental Design""; ""6 Resource Issues""; ""References""; ""About the Authors""; ""Appendix A: Public Workshop Agenda, and Biographical Information about the Speakers,""The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies--including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)--be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies. BioterrorismResearchChemical warfareBioterrorismResearch.Chemical warfare.363.325National Research Council (U.S.).Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents.National Research Council (U.S.).Board on Life Sciences.Institute for Laboratory Animal Research (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910971069003321Overcoming challenges to develop countermeasures against aerosolized bioterrorism agents4358238UNINA